{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:07:02Z","timestamp":1787774822871,"version":"build-2784847793"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10461-025-04821-9","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T13:07:38Z","timestamp":1753103258000},"page":"3838-3851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preferences for Long-Acting HIV Pre-Exposure Prophylaxis among Women of Reproductive Age in Low- and Middle-income Countries: A Systematic Review"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4976-5096","authenticated-orcid":false,"given":"Sophia","family":"Ngugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Echoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Were","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kazungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"4821_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics \u2014 Fact sheet [Internet]. [cited 2024 Aug 2]. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"4821_CR2","unstructured":"UNAIDS. Global HIV statistics. 2023."},{"key":"4821_CR3","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26115","volume":"26","author":"NM Mgodi","year":"2023","unstructured":"Mgodi NM, Murewanhema G, Moyo E, Samba C, Musuka G, Dzinamarira T, et al. Advancing the use of Long-Acting Extended Delivery formulations for HIV prevention in sub-Saharan Africa: challenges, opportunities, and recommendations. J Int AIDS Soc. 2023;26: e26115.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR4","doi-asserted-by":"publisher","unstructured":"Bhushan NL, Ridgeway K, Luecke EH, Palanee-Phillips T, Montgomery ET, Minnis AM. 2023. Synthesis of end-user research to inform future multipurpose prevention technologies in sub-Saharan Africa: a scoping review. Frontiers in Reproductive Health [Internet]. https:\/\/doi.org\/10.3389\/frph.2023.1156864","DOI":"10.3389\/frph.2023.1156864"},{"key":"4821_CR5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijregi.2022.08.009","volume":"5","author":"G Murewanhema","year":"2022","unstructured":"Murewanhema G, Musuka G, Moyo P, Moyo E, Dzinamarira T. HIV and adolescent girls and young women in sub-Saharan Africa: A call for expedited action to reduce new infections. IJID Regions. 2022;5:30\u20132.","journal-title":"IJID Regions"},{"key":"4821_CR6","unstructured":"UN Women. HIV and AIDS [Internet]. UN Women\u2013 Headquarters. n.d. [cited 2024 Aug 2]. Available from: https:\/\/www.unwomen.org\/en\/what-we-do\/hiv-and-aids"},{"key":"4821_CR7","doi-asserted-by":"crossref","first-page":"27249","DOI":"10.3402\/gha.v8.27249","volume":"8","author":"V Choudhry","year":"2015","unstructured":"Choudhry V, Ambresin A-E, Nyakato VN, Agardh A. Transactional sex and HIV risks - evidence from a cross-sectional national survey among young people in Uganda. Glob Health Action. 2015;8:27249.","journal-title":"Glob Health Action"},{"key":"4821_CR8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/infdis\/jiy113","volume":"218","author":"KA Thomson","year":"2018","unstructured":"Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis. 2018;218:16\u201325.","journal-title":"J Infect Dis"},{"key":"4821_CR9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1473-3099(15)00429-6","volume":"16","author":"EH Byrne","year":"2016","unstructured":"Byrne EH, Cohen KE, Moodley A, Padavattan N, Ismail N, Bowman BA, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis. 2016;16:441\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4821_CR10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001778","volume":"12","author":"CS Morrison","year":"2015","unstructured":"Morrison CS, Chen P-L, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med. 2015;12: e1001778.","journal-title":"PLoS Med"},{"key":"4821_CR11","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QAD.0000000000003803","volume":"38","author":"LF Johnson","year":"2024","unstructured":"Johnson LF, Myer L, Jamieson L, Meyer-Rath G, Delany-Moretlwe S, Joseph DD. The potential benefits of long-acting injectable cabotegravir in pregnant and breastfeeding women and their infants. AIDS. 2024;38:589\u201394.","journal-title":"AIDS"},{"key":"4821_CR12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001608","volume":"11","author":"AL Drake","year":"2014","unstructured":"Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med. 2014;11: e1001608.","journal-title":"PLoS Med"},{"key":"4821_CR13","unstructured":"WHO. Women of reproductive age (15-49 years) population (thousands) [Internet]. [cited 2025 Apr 15]. Available from: https:\/\/www.who.int\/data\/gho\/indicator-metadata-registry\/imr-details\/women-of-reproductive-age-(15-49-years)-population-(thousands)"},{"key":"4821_CR14","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/S2352-3018(19)30433-3","volume":"7","author":"CA Koss","year":"2020","unstructured":"Koss CA, Charlebois ED, Ayieko J, Kwarisiima D, Kabami J, Balzer LB, et al. Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study. Lancet HIV. 2020;7:e249\u201361.","journal-title":"Lancet HIV"},{"key":"4821_CR15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women. N Engl J Med. 2012;367:399\u2013410.","journal-title":"N Engl J Med"},{"key":"4821_CR16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423\u201334.","journal-title":"N Engl J Med"},{"key":"4821_CR17","doi-asserted-by":"crossref","unstructured":"Schaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. The Lancet HIV. 2021; 8: e502\u201310.","DOI":"10.1016\/S2352-3018(21)00127-2"},{"key":"4821_CR18","unstructured":"Joint United Nations Programme on HIV\/AIDS. The urgency of now: AIDS at a crossroads [Internet]. Geneva; 2024. Available from: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf"},{"key":"4821_CR19","doi-asserted-by":"crossref","unstructured":"Peck ME. Progress toward UNAIDS global HIV pre-exposure prophylaxis targets: CDC-supported oral pre-exposure prophylaxis\u201437 countries, 2017\u2500 2023. MMWR Morbidity and Mortality Weekly Report. 2024; 73.","DOI":"10.15585\/mmwr.mm7347a3"},{"key":"4821_CR20","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25909","volume":"25","author":"Y Mayanja","year":"2022","unstructured":"Mayanja Y, Kamacooko O, Lunkuse JF, Muturi-Kioi V, Buzibye A, Omali D, et al. Oral pre-exposure prophylaxis preference, uptake, adherence and continuation among adolescent girls and young women in Kampala, Uganda: a prospective cohort study. J Int AIDS Soc. 2022;25: e25909.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR21","doi-asserted-by":"crossref","first-page":"e1004097","DOI":"10.1371\/journal.pmed.1004097","volume":"19","author":"J de Tapsoba","year":"2022","unstructured":"de Tapsoba J, D, Cover J, Obong\u2019o C, Brady M, Cressey TR, Mori K, et al. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study. PLoS Med. 2022;19:e1004097.","journal-title":"PLoS Med"},{"key":"4821_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-20975-y","author":"S Kawuma","year":"2024","unstructured":"Kawuma S, Katwesigye R, Walusaga H, Akatukunda P, Nangendo J, Kabugo C, et al. Determinants to continuation on HIV pre-exposure propylaxis among female sex workers at a referral hospital in Uganda: a mixed methods study using Com-b model. Res Sq. 2024. https:\/\/doi.org\/10.1186\/s12889-024-20975-y.","journal-title":"Res Sq"},{"key":"4821_CR23","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","volume":"37","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: A narrative review. Adv Ther. 2020;37:1778\u2013811.","journal-title":"Adv Ther"},{"key":"4821_CR24","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40265-019-01143-8","volume":"79","author":"I Hodges-Mameletzis","year":"2019","unstructured":"Hodges-Mameletzis I, Fonner VA, Dalal S, Mugo N, Msimanga-Radebe B, Baggaley R. Pre-exposure prophylaxis for HIV prevention in women: Current status and future directions. Drugs. 2019;79:1263\u201376.","journal-title":"Drugs"},{"key":"4821_CR25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779\u201389.","journal-title":"Lancet"},{"key":"4821_CR26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10508-023-02712-5","volume":"53","author":"LA Nydegger","year":"2024","unstructured":"Nydegger LA, Kidane H, Benitez S, Yuan M, Claborn KR. A qualitative exploration of PrEP interests, barriers, and interventions among black and Latina cisgender women in the U.S. Arch Sex Behav. 2024;53:771\u201383.","journal-title":"Arch Sex Behav"},{"key":"4821_CR27","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/tmi.13651","volume":"26","author":"B Dawkins","year":"2021","unstructured":"Dawkins B, Renwick C, Ensor T, Shinkins B, Jayne D, Meads D. What factors affect patients\u2019 ability to access healthcare? An overview of systematic reviews. Tropical Med Int Health. 2021;26:1177\u201388.","journal-title":"Tropical Med Int Health"},{"key":"4821_CR28","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1038\/s41598-022-11020-2","volume":"12","author":"M Gunawardana","year":"2022","unstructured":"Gunawardana M, Remedios-Chan M, Sanchez D, Webster S, Castonguay AE, Webster P, et al. Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis. Sci Rep. 2022;12:8224.","journal-title":"Sci Rep"},{"key":"4821_CR29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JNC.0000000000000460","volume":"35","author":"M Haines","year":"2024","unstructured":"Haines M, Vandyk A, Skidmore B, Orser L, O\u2019Byrne P. A systematic review of oral pre-exposure prophylaxis HIV adherence interventions. J Assoc Nurses AIDS Care. 2024;35:309.","journal-title":"J Assoc Nurses AIDS Care"},{"key":"4821_CR30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11904-021-00576-9","volume":"18","author":"E Irungu","year":"2021","unstructured":"Irungu E, Khoza N, Velloza J. Multi-level interventions to promote oral pre-exposure prophylaxis use among adolescent girls and young women: a review of recent research. Curr HIV\/AIDS Rep. 2021;18:490\u20139.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4821_CR31","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.amepre.2021.04.036","volume":"61","author":"LE Garrison","year":"2021","unstructured":"Garrison LE, Haberer JE. Pre-exposure prophylaxis uptake, adherence, and persistence: A narrative review of interventions in the U.S. Amr J Prevent Med. 2021;61:S73-86.","journal-title":"Amr. J. Prevent. Med."},{"key":"4821_CR32","unstructured":"Prevention Product Manager. Evaluating, scaling up and enhancing strategies for supporting continuation and effective use [Internet]. 2020. Available from: https:\/\/www.prepwatch.org\/wp-content\/uploads\/2021\/01\/2019_2020_ThinkTankReport.pdf"},{"issue":"2","key":"4821_CR33","volume":"26","author":"L Lorenzetti","year":"2023","unstructured":"Lorenzetti L, Dinh N, van der Straten A, Fonner V, Ridgeway K, Rodolph M, et al. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition. J Int AIDS Soc. 2023;26(2): e26107.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR34","doi-asserted-by":"crossref","first-page":"e857","DOI":"10.1016\/S2352-3018(22)00251-X","volume":"9","author":"L Jamieson","year":"2022","unstructured":"Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, et al. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022;9:e857\u201367.","journal-title":"Lancet HIV"},{"key":"4821_CR35","unstructured":"AVAC. Pre-exposure prophylaxis and adolescent girls and young women in eastern and southern Africa: The latest insight. New York: AVAC; 2024."},{"key":"4821_CR36","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","volume":"375","author":"A Nel","year":"2016","unstructured":"Nel A, van Niekerk N, Kapiga S, Bekker L-G, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133\u201343.","journal-title":"N Engl J Med"},{"key":"4821_CR37","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","volume":"375","author":"JM Baeten","year":"2016","unstructured":"Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121\u201332.","journal-title":"N Engl J Med"},{"key":"4821_CR38","volume":"23","author":"ER Brown","year":"2020","unstructured":"Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, et al. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. J Int AIDS Soc. 2020;23: e25634.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR39","doi-asserted-by":"crossref","unstructured":"Johnson LM, Krovi SA, Li L, Girouard N, Demkovich ZR, Myers D, et al. Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV pre-exposure prophylaxis (PrEP). Pharmaceutics. 2019; 11.","DOI":"10.3390\/pharmaceutics11070315"},{"key":"4821_CR40","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1080\/17425247.2022.2135699","volume":"19","author":"V Agrahari","year":"2022","unstructured":"Agrahari V, Anderson SM, Peet MM, Wong AP, Singh ON, Doncel GF, et al. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. Expert Opin Drug Deliv. 2022;19:1365\u201380.","journal-title":"Expert Opin Drug Deliv"},{"key":"4821_CR41","unstructured":"PrEP| AVAC [Internet]. [cited 2024 Feb 22]. Available from: https:\/\/avac.org\/prevention-option\/prep\/"},{"key":"4821_CR42","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26126","volume":"26","author":"S Delany-Moretlwe","year":"2023","unstructured":"Delany-Moretlwe S, Flexner C, Bauermeister JA. Advancing use of long-acting and extended delivery HIV prevention and treatment regimens. J Int AIDS Soc. 2023;26: e26126.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR43","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/QAI.0000000000002793","volume":"88","author":"K Ngure","year":"2021","unstructured":"Ngure K, Mugo NR, Bukusi EA, Kiptinness C, Oware K, Gakuo S, et al. Pills, injections, rings, or implants? PrEP formulation preferences of PrEP-experienced African women for HIV prevention. J Acquir Immune Defic Syndr. 2021;88:e30\u20132.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"4821_CR44","doi-asserted-by":"crossref","first-page":"20875","DOI":"10.7448\/IAS.19.1.20875","volume":"19","author":"EH Luecke","year":"2016","unstructured":"Luecke EH, Cheng H, Woeber K, Nakyanzi T, Mudekunye-Mahaka IC, van der Straten A. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study. J Int AIDS Soc. 2016;19:20875.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR45","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1080\/09540121.2019.1587356","volume":"31","author":"KB Biello","year":"2019","unstructured":"Biello KB, Edeza A, Salhaney P, Biancarelli DL, Mimiaga MJ, Drainoni ML, et al. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. AIDS Care. 2019;31:1214\u201320.","journal-title":"AIDS Care"},{"key":"4821_CR46","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/QAD.0000000000001859","volume":"32","author":"MJ Siedner","year":"2018","unstructured":"Siedner MJ, Hettema A, Hughey A, Oldenburg CE, Kohler S, B\u00e4rnighausen K, et al. Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland. AIDS. 2018;32:1541\u20132.","journal-title":"AIDS"},{"key":"4821_CR47","volume":"51","author":"LPL Wulandari","year":"2022","unstructured":"Wulandari LPL, He SY, Fairley CK, Bavinton BR, Marie-Schmidt H, Wiseman V, et al. Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments. EClinicalMedicine. 2022;51: 101507.","journal-title":"EClinicalMedicine"},{"key":"4821_CR48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12905-023-02181-x","volume":"23","author":"EN Browne","year":"2023","unstructured":"Browne EN, Manenzhe K, Makoni W, Nkomo S, Mahaka I, Ahmed K, et al. Incorporating end-users\u2019 voices into the development of an implant for HIV prevention: a discrete choice experiment in South Africa and Zimbabwe. BMC Womens Health. 2023;23:58.","journal-title":"BMC Womens Health"},{"key":"4821_CR49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1186\/s12879-022-07907-0","volume":"22","author":"MS Brown","year":"2022","unstructured":"Brown MS, Hanif H, Little KM, Clark MR, Thurman AR, Flomen L, et al. End-user research in support of long-acting systemic antiretroviral delivery systems: insights from qualitative research with providers and target users in South Africa. BMC Infect Dis. 2022;22:919.","journal-title":"BMC Infect Dis"},{"key":"4821_CR50","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"4821_CR51","unstructured":"CASP. Critical Appraisal Skills Programme Checklists [Internet]. CASP - Critical Appraisal Skills Programme. n.d. [cited 2024 Aug 1]. Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/"},{"key":"4821_CR52","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1186\/s12889-023-16955-3","volume":"23","author":"L Fynn","year":"2023","unstructured":"Fynn L, Gill K, Wallace M, Atujuna M, Duyver M, Ngcobo P, et al. \u201cIt\u2019s already in your body and it\u2019s preventing\u201d: a qualitative study of African female adolescent\u2019s acceptability and preferences for proxy HIV prevention methods in Cape Town. South Africa BMC Public Health. 2023;23:2143.","journal-title":"South Africa BMC Public Health"},{"key":"4821_CR53","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25626","volume":"23","author":"K Gill","year":"2020","unstructured":"Gill K, Happel A-U, Pidwell T, Mendelsohn A, Duyver M, Johnson L, et al. An open-label, randomized crossover study to evaluate the acceptability and preference for contraceptive options in female adolescents, 15 to 19 years of age in Cape Town, as a proxy for HIV prevention methods (UChoose). J Int AIDS Soc. 2020;23: e25626.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR54","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1007\/s10461-023-04072-6","volume":"27","author":"CJ Jansen van Vuuren","year":"2023","unstructured":"Jansen van Vuuren CJ, Lewis L, Harkoo I, Dawood H, Mansoor LE. Experience with contraceptive dosage forms and interest in novel PrEP technologies in women. AIDS Behav. 2023;27:3596\u2013602.","journal-title":"AIDS Behav"},{"key":"4821_CR55","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1007\/s10461-022-03658-w","volume":"26","author":"KM Little","year":"2022","unstructured":"Little KM, Flomen L, Hanif H, Anderson SM, Thurman AR, Clark MR, et al. HIV pre-exposure prophylaxis implant stated preferences and priorities: Results of a discrete choice experiment among women and adolescent girls in Gauteng Province. South Africa AIDS Behav. 2022;26:3099\u2013109.","journal-title":"South Africa AIDS Behav"},{"key":"4821_CR56","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25528","volume":"23","author":"AM Minnis","year":"2020","unstructured":"Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020;23: e25528.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR57","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s10461-023-04202-0","volume":"28","author":"KM Little","year":"2024","unstructured":"Little KM, Hanif H, Anderson SM, Clark MR, Gustafson K, Doncel GF. Preferences for long-acting PrEP products among women and girls: A quantitative survey and discrete choice experiment in Eswatini, Kenya, and South Africa. AIDS Behav. 2024;28:936\u201350.","journal-title":"AIDS Behav"},{"key":"4821_CR58","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/QAD.0000000000001452","volume":"31","author":"ET Montgomery","year":"2017","unstructured":"Montgomery ET, van der Straten A, Chitukuta M, Reddy K, Woeber K, Atujuna M, et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. AIDS. 2017;31:1159\u201367.","journal-title":"AIDS"},{"key":"4821_CR59","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/apc.2017.0075","volume":"31","author":"A van der Straten","year":"2017","unstructured":"van der Straten A, Shapley-Quinn MK, Reddy K, Cheng H, Etima J, Woeber K, et al. Favoring \u201cPeace of Mind\u201d: A qualitative study of African women\u2019s HIV prevention product formulation preferences from the MTN-020\/ASPIRE trial. AIDS Patient Care STDS. 2017;31:305\u201314.","journal-title":"AIDS Patient Care STDS"},{"key":"4821_CR60","volume":"26","author":"NJ Wara","year":"2023","unstructured":"Wara NJ, Mvududu R, Marwa MM, G\u00f3mez L, Mashele N, Orrell C, et al. Preferences and acceptability for long-acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya. J Int AIDS Soc. 2023;26: e26088.","journal-title":"J Int AIDS Soc"},{"key":"4821_CR61","doi-asserted-by":"crossref","first-page":"e779","DOI":"10.1016\/S2352-3018(23)00227-8","volume":"10","author":"G Nair","year":"2023","unstructured":"Nair G, Celum C, Szydlo D, Brown ER, Akello CA, Nakalega R, et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Lancet HIV. 2023;10:e779\u201389.","journal-title":"Lancet HIV"},{"key":"4821_CR62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287525","volume":"18","author":"K Ngure","year":"2023","unstructured":"Ngure K, Friedland BA, Szydlo DW, Roberts ST, Garcia M, Levy L, et al. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034\/IPM-045 study). PLoS ONE. 2023;18: e0287525.","journal-title":"PLoS ONE"},{"key":"4821_CR63","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s10461-019-02715-1","volume":"24","author":"EN Browne","year":"2020","unstructured":"Browne EN, Montgomery ET, Mansfield C, Boeri M, Mange B, Beksinska M, et al. Efficacy is not everything: eliciting women\u2019s preferences for a vaginal HIV prevention product using a discrete-choice experiment. AIDS Behav. 2020;24:1443\u201351.","journal-title":"AIDS Behav"},{"key":"4821_CR64","doi-asserted-by":"crossref","first-page":"e058611","DOI":"10.1136\/bmjopen-2021-058611","volume":"12","author":"SW Beckham","year":"2022","unstructured":"Beckham SW, Mantsios A, Galai N, Likindikoki S, Mbwambo J, Davis W, et al. Acceptability of multiple modalities of pre-exposure prophylaxis (PrEP) among female sex workers in Tanzania: a mixed-methods study. BMJ Open. 2022;12:e058611.","journal-title":"BMJ Open"},{"key":"4821_CR65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023272","volume":"9","author":"G Harling","year":"2019","unstructured":"Harling G, Muya A, Ortblad KF, Mashasi I, Dambach P, Ulenga N, et al. HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: cross-sectional survey. BMJ Open. 2019;9: e023272.","journal-title":"BMJ Open"},{"key":"4821_CR66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0000981","volume":"2","author":"A Mantsios","year":"2022","unstructured":"Mantsios A, Muraleetharan O, Donastorg Y, Perez M, Gomez H, Shembilu C, et al. \u201cShe is the one who knows\u201d: A qualitative exploration of oral and injectable PrEP as part of a community empowerment approach to HIV prevention among female sex workers in the Dominican Republic and Tanzania. PLOS Glob Public Health. 2022;2: e0000981.","journal-title":"PLOS Glob Public Health"},{"key":"4821_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-020-05399-4","volume":"20","author":"P Vickerman","year":"2020","unstructured":"Vickerman P, Quaife M, Kilbourne-Brook M, Mvundura M, Eakle R, Terris-Prestholt F. HIV prevention is not all about HIV\u2013using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. BMC Infect Dis. 2020;20:1\u201311.","journal-title":"BMC Infect Dis"},{"key":"4821_CR68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/apc.2020.0164","volume":"35","author":"MM Philbin","year":"2021","unstructured":"Philbin MM, Parish C, Bergen S, Kerrigan D, Kinnard EN, Reed SE, et al. A qualitative exploration of women\u2019s interest in long-acting injectable antiretroviral therapy across six cities in the Women\u2019s Interagency HIV Study: Intersections with current and past injectable medication and substance use. AIDS Patient Care STDS. 2021;35:23\u201330.","journal-title":"AIDS Patient Care STDS"},{"key":"4821_CR69","doi-asserted-by":"crossref","unstructured":"Johnson AK, Ott E, Friedman EE, Pandiani A, Moore A, Alvarez I, et al. 2025. Exploring pre-exposure prophylaxis (PrEP) modality preferences among black cisgender women attending family planning clinics in Chicago via a cross-sectional mixed-methods study. BMJ Public Health. 3","DOI":"10.1136\/bmjph-2023-000809"},{"key":"4821_CR70","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1007\/s10461-021-03571-8","volume":"26","author":"WC Irie","year":"2022","unstructured":"Irie WC, Calabrese SK, Patel RR, Mayer KH, Geng EH, Marcus JL. Preferences for HIV pre-exposure prophylaxis products among black women in the U.S. AIDS Behav. 2022;26:2212\u201323.","journal-title":"AIDS Behav"},{"key":"4821_CR71","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.01.24305173","author":"B Pfau","year":"2024","unstructured":"Pfau B, Saravis BAA, Cox SN, Wu L, Wittenauer R, Callen E, et al. User preferences on long-acting pre-exposure prophylaxis for HIV prevention in sub-Saharan Africa A scoping review. Medrxiv. 2024. https:\/\/doi.org\/10.1101\/2024.04.01.24305173.","journal-title":"Medrxiv"},{"key":"4821_CR72","doi-asserted-by":"crossref","first-page":"1221101","DOI":"10.3389\/frph.2023.1221101","volume":"5","author":"L Fairlie","year":"2023","unstructured":"Fairlie L, Lavies D, Kalk E, Mhlongo O, Patel F, Technau K-G, et al. Safety surveillance for PrEP in pregnant and breastfeeding women. Front Reprod Health. 2023;5:1221101.","journal-title":"Front Reprod Health"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04821-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-025-04821-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-025-04821-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T02:49:34Z","timestamp":1762138174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-025-04821-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4821"],"URL":"https:\/\/doi.org\/10.1007\/s10461-025-04821-9","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"7 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}